↓ Skip to main content

Alternative forms of hydration in patients with cancer in the last days of life: study protocol for a randomised controlled trial

Overview of attention for article published in Trials, October 2015
Altmetric Badge

Mentioned by

twitter
5 X users

Citations

dimensions_citation
12 Dimensions

Readers on

mendeley
143 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Alternative forms of hydration in patients with cancer in the last days of life: study protocol for a randomised controlled trial
Published in
Trials, October 2015
DOI 10.1186/s13063-015-0988-3
Pubmed ID
Authors

Andrew Davies, Melanie Waghorn, Julia Boyle, Ann Gallagher, Sigurd Johnsen

Abstract

The provision of clinically assisted hydration at the end of life is one of the most contentious issues in medicine, and indeed within the general population. The reasons for contention include: a) the lack of evidence for or against; b) the disparate opinions of healthcare professionals; and c) the generally positive opinions of patients and their carers about clinically assisted hydration. The study is a cluster randomised trial to assess the feasibility of conducting an adequately powered, randomised controlled trial of clinically assisted hydration in patients with cancer in the last days of life. Twelve sites, four National Health Service (NHS) hospitals and eight NHS/voluntary sector hospices in the United Kingdom, will be randomised to give either standard intervention A: continuance of oral intake and regular mouth care, or standard intervention B: continuance of oral intake, regular mouth care and clinically assisted hydration. Patients will be included if they: i) have a diagnosis of cancer; ii) are aged ≥ 18 yr; iii) have an estimated prognosis of ≤ 1 week and iv) are unable to maintain sufficient oral intake (1 L per day, measured/estimated); and v) are able to give informed consent. Patients will be excluded if they have contra-indications to receiving clinically assisted hydration. The primary endpoint of interest is the frequency of hyperactive delirium ('terminal agitation'), and this will be assessed using the Modified Richmond Agitation and Sedation Scale (administered every four hours). Other data to be collected include the frequency of pain, respiratory secretions ('death rattle'), dyspnoea, nausea and vomiting, adverse effects to clinically assisted hydration and overall survival. In addition, data will be collected on the use of anti-psychotic drugs, sedative drugs, analgesics, anti-secretory drugs and other end-of-life medication. The study has obtained full ethical approval. A randomised controlled trial of clinically assisted hydration in end-of-life care is urgently required. This feasibility study will allow methodological and ethical issues to be understood and addressed to ensure that a robust, adequately powered, randomised controlled trial is designed. ClinicalTrials.gov NCT02344927 (registered 4 June 2014).

X Demographics

X Demographics

The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 143 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 <1%
Portugal 1 <1%
Unknown 141 99%

Demographic breakdown

Readers by professional status Count As %
Student > Master 27 19%
Student > Ph. D. Student 17 12%
Student > Bachelor 17 12%
Researcher 13 9%
Other 11 8%
Other 26 18%
Unknown 32 22%
Readers by discipline Count As %
Medicine and Dentistry 49 34%
Nursing and Health Professions 24 17%
Psychology 12 8%
Biochemistry, Genetics and Molecular Biology 4 3%
Pharmacology, Toxicology and Pharmaceutical Science 4 3%
Other 15 10%
Unknown 35 24%